Yahoo
ASX - Delayed Quote AUD

Amplia Therapeutics Limited (ATX.AX)

0.0840 0.0000 (0.00%)
At close: 4:10:27 PM GMT+11
Chart Range Bar
Loading chart for ATX.AX
  • Previous Close 0.0840
  • Open 0.0850
  • Bid 0.0800 x --
  • Ask 0.0840 x --
  • Day's Range 0.0820 - 0.0850
  • 52 Week Range 0.0760 - 0.2750
  • Volume 736,376
  • Avg. Volume 1,119,317
  • Market Cap (intraday) 43.118M
  • Beta (5Y Monthly) -0.33
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 0.42

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

www.ampliatx.com

--

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

ATX.AX
44.00%
S&P/ASX 200 [XJO] (^AXJO)
1.63%

1-Year Return

ATX.AX
37.78%
S&P/ASX 200 [XJO] (^AXJO)
0.43%

3-Year Return

ATX.AX
3.70%
S&P/ASX 200 [XJO] (^AXJO)
26.92%

5-Year Return

ATX.AX
56.46%
S&P/ASX 200 [XJO] (^AXJO)
19.80%

Analyst Insights

View More

Analyst Price Targets

0.42
0.42 Average
0.0840 Current
0.42 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -160.86%

  • Return on Assets (ttm)

    -16.29%

  • Return on Equity (ttm)

    -25.48%

  • Revenue (ttm)

    4.79M

  • Net Income Avi to Common (ttm)

    -7.71M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    27.85M

  • Total Debt/Equity (mrq)

    0.86%

  • Levered Free Cash Flow (ttm)

    -6.48M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: